Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors
LTRN(NASDAQ:LTRN) DALLAS--(BUSINESS WIRE)--Clinical Trial Results, LP-184
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial
LTRNDALLAS--(BUSINESS WIRE)--Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma Inc. (NASDAQ: LTRN), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase Ib/2a clinical trial to evaluate STAR-001 (LP-184) in combination with spironolactone for patients with glioblastoma multiforme (GBM) at first progression. The planned Phase Ib/2a clinical trial (IND 178511) is designed to investigate the safety, to
Lantern Pharma Announces Public Release of Transformative, Advanced AI Module for Blood-Brain Barrier Permeability Prediction, predictBBB.ai™
LTRNDALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a pioneering artificial intelligence company transforming oncology drug discovery and development, today announced the public release of its AI module for predicting blood-brain barrier (BBB) permeability of small molecules with unprecedented accuracy and scalability – predictBBB.ai™. This critical advancement addresses one of pharmaceutical development's most persistent challenges—that only 2-6% of small-molecule drugs can successful
Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years
LTRNDALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announces remarkable clinical observations for a patient in Lantern’s Phase 2 HARMONIC™ clinical trial. A 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) has achieved a durable complete response in their target cancer lesions following treatment with LP-300 in combination with standard-o
Lantern Pharma Announces Preclinical Data For LP-184 In Atypical Teratoid Rhabdoid Tumors, Rare And Aggressive Pediatric Brain Cancer
LTRNLantern Pharma Q1 EPS $(0.42) Beats $(0.49) Estimate
LTRNLantern Pharma's Earnings Outlook
LTRNEXCLUSIVE: Lantern Pharma Tell Benzinga 'Drug candidate LP-184 to be evaluated in combination with immune checkpoint inhibitors in biomarker-defined NSCLC patients with KEAP1 and/or STK11 mutations and low PD-L1 expression'
LTRNEXCLUSIVE: Lantern Pharma Tell Benzinga Co. Secures FDA Clerance For Planned Phase 1b/2 Trial Of LP-184 In Biomarker-Defined, Treatment-Resistant NSCLC Patients With High Unmet Clinical Need
LTRNLantern Pharma Receives Clearance Of IND Application From FDA For Phase 1b/2 Clinical Trial For LP-184 In Triple Negative Breast Cancer
LTRNEXCLUSIVE: Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial
LTRNLantern Pharma's LP-184 advances to Phase 1b/2 trial in TNBC after FDA clearance, adding to its Fast Track and Rare Pediatric Disease designations.
EXCLUSIVE: Lantern Pharma Tells Benzinga ''The phase 1b/2 clinical trial plans to evaluate LP-184 in recurrent TNBC patients as both monotherapy and in combination with olaparib'
LTRNEXCLUSIVE: Lantern Pharma Tells Benzinga Co. Advances Drug Candidate LP-184 With IND Clearance For Phase 1b/2 Trial In Triple Negative Breast Cancer
LTRNLake Street Initiates Coverage On Lantern Pharma with Buy Rating, Announces Price Target of $25
LTRNLantern Pharma Q4 2024 GAAP EPS $(0.54) Misses $(0.51) Estimate
LTRNPreview: Lantern Pharma's Earnings
LTRNLantern Pharma Doses First Patient In Japan For Expansion Cohort In Phase 2 HARMONIC Clinical Trial Of LP-300 In Never-Smoker NSCLC Patients
LTRNLantern Pharma Touts Encouraging Positive Efficacy For Pancreatic Cancer Candidate
LTRNLantern Pharma To Present Preclinical Data On The Efficacy Of LP-184 For Pancreatic Cancer At The AACR Special Conference For Pancreatic Cancer September 14 4:00pm ET
LTRNRecap: Lantern Pharma Q1 Earnings
LTRNLantern Pharma (NASDAQ:LTRN) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Lantern Pharma missed estimated earnings by 31.03%, reporting an EPS of $-0.38 versus an estimate of $-0.29.
Lantern Pharma Q1 EPS $(0.38) Misses $(0.29) Estimate
LTRNLantern Pharma Earnings Preview
LTRNLantern Pharma (NASDAQ:LTRN) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement.
Analysts estimate that Lantern Pharma will report an earnings per share (EPS) of $-0.29.
